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Abstract
Background: Mononucleotide tracts in the coding regions of the TGFBR2 and BAX genes are commonly mutated in
microsatellite instability-high (MSI-high) colon cancers. The receptor TGFBR2 plays an important role in the TGFB1
(transforming growth factor-b, TGF-b) signaling pathway, and BAX plays a key role in apoptosis. However, a role of TGFBR2
or BAX mononucleotide mutation in colorectal cancer as a prognostic biomarker remains uncertain.
Methodology/Principal Findings: We utilized a database of 1072 rectal and colon cancers in two prospective cohort studies
(the Nurses’ Health Study and the Health Professionals Follow-up Study). Cox proportional hazards model was used to
compute mortality hazard ratio (HR), adjusted for clinical, pathological and molecular features including the CpG island
methylator phenotype (CIMP), LINE-1 methylation, and KRAS, BRAF and PIK3CA mutations. MSI-high was observed in 15%
(162/1072) of all colorectal cancers. TGFBR2 and BAX mononucleotide mutations were detected in 74% (117/159) and 30%
(48/158) of MSI-high tumors, respectively. In Kaplan-Meier analysis as well as univariate and multivariate Cox regression
analyses, compared to microsatellite stable (MSS)/MSI-low cases, MSI-high cases were associated with superior colorectal
cancer-specific survival [adjusted HR, 0.34; 95% confidence interval (CI), 0.20–0.57] regardless of TGFBR2 or BAX mutation
status. Among MSI-high tumors, TGFBR2 mononucleotide mutation was associated with CIMP-high independent of other
variables [multivariate odds ratio, 3.57; 95% CI, 1.66–7.66; p=0.0011].
Conclusions: TGFBR2 or BAX mononucleotide mutations are not associated with the patient survival outcome in MSI-high
colorectal cancer. Our data do not support those mutations as prognostic biomarkers (beyond MSI) in colorectal carcinoma.
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Introduction
Colorectal cancer represents a group of molecularly heteroge-
neous diseases with different sets of epigenetic and genetic
abnormalities. High degree of microsatellite instability (MSI-high)
is caused by deficiency of DNA mismatch repair system, and
observed in approximately 15% of colorectal cancers. MSI testing is
widely used as screening for patients with Lynch syndrome/
hereditary nonpolyposis colorectal cancer (HNPCC) [1,2,3]. In
addition, MSI is generally accepted as a prognostic marker [4], and
likely a predictive marker for resistance to 5-fluorouracil [5]. Since
Markowitz et al. [6] discovered mutations in the coding mononu-
cleotide repeats of TGFBR2 in MSI-high colon cancer cells, similar
mutations of coding mononucleotide repeats in many other genes
(including BAX, MSH3, MSH6, IGF2R and PTEN) have been found
in MSI-high colorectal cancers [3,7,8,9]. Among those genes,
mononucleotide coding repeats of TGFBR2(A)10and BAX (G)8 have
frequent frameshift mutations resulting in the production of
truncated, inactive form of the proteins [3,10]. TGFB1 (transform-
ing growth factor-b,T G F - b) and its receptor TGFBR2 constitute a
signaling pathway that regulates the transcription of many genes,
and functions as a tumor suppressor [11,12,13,14] and an immune
response regulator [15]. BAX generally promotes apoptosis and
antagonizes the effect of BCL2 [16,17,18]. Thus, inactivation of
TGFBR2 or BAX may contribute to tumor progression.
Several previous studies have examined the prognostic role of
TGFBR2 or BAX mononucleotide mutations in MSI-high
colorectal cancers, yielding inconclusive results due to limited
statistical power in most studies [19,20,21,22,23,24,25] (Table 1).
All but one previous study [23] examined the prognostic role of
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25062T
a
b
l
e
1
.
S
t
u
d
i
e
s
o
n
p
r
o
g
n
o
s
t
i
c
s
i
g
n
i
f
i
c
a
n
c
e
o
f
T
G
F
B
R
2
o
r
B
A
X
m
o
n
o
n
u
c
l
e
o
t
i
d
e
m
u
t
a
t
i
o
n
i
n
M
S
I
-
h
i
g
h
c
o
l
o
r
e
c
t
a
l
c
a
n
c
e
r
.
R
e
f
.
A
u
t
h
o
r
s
(
y
e
a
r
)
N
o
.
o
f
h
o
s
p
i
t
a
l
s
S
a
m
p
l
e
s
i
z
e
f
o
r
M
S
I
d
e
t
e
r
m
i
n
a
t
i
o
n
D
i
s
e
a
s
e
s
t
a
g
e
C
h
e
m
o
t
h
e
r
a
p
y
M
S
I
-
h
i
g
h
c
a
s
e
s
M
o
n
o
n
u
c
l
e
o
t
i
d
e
m
u
t
a
t
i
o
n
s
i
n
M
S
I
-
h
i
g
h
c
o
l
o
r
e
c
t
a
l
c
a
n
c
e
r
O
t
h
e
r
m
o
l
e
c
u
l
a
r
c
o
v
a
r
i
a
t
e
s
a
n
d
n
o
t
e
s
N
O
S
e
v
e
n
t
s
C
S
e
v
e
n
t
s
T G F B R 2
B A X
C
a
s
e
s
n
u
m
b
e
r
/
M
S
I
-
h
i
g
h
c
a
s
e
s
5
-
y
e
a
r
s
u
r
v
i
v
a
l
P
v
a
l
u
e
b
y
l
o
g
-
r
a
n
k
t
e
s
t
(
v
s
.
w
i
l
d
t
y
p
e
c
a
s
e
s
)
M
u
l
t
i
v
a
r
i
a
t
e
H
R
(
9
5
%
C
I
)
P
v
a
l
u
e
(
v
s
.
w
i
l
d
-
t
y
p
e
c
a
s
e
s
)
C
a
s
e
s
n
u
m
b
e
r
/
M
S
I
-
h
i
g
h
c
a
s
e
s
5
-
y
e
a
r
s
u
r
v
i
v
a
l
P
v
a
l
u
e
b
y
l
o
g
-
r
a
n
k
t
e
s
t
(
v
s
.
w
i
l
d
t
y
p
e
c
a
s
e
s
)
M
u
l
t
i
v
a
r
i
a
t
e
H
R
(
9
5
%
C
I
)
P
v
a
l
u
e
(
v
s
.
w
i
l
d
-
t
y
p
e
c
a
s
e
s
)
[
1
9
]
I
a
c
o
p
e
t
t
a
e
t
a
l
.
(
1
9
9
8
)
1
2
1
0
D
u
k
e
s
’
B
a
n
d
C
-
3
7
-
-
3
2
/
3
7
O
S
a
t
t
h
e
e
n
d
p
o
i
n
t
*
7
2
%
(
v
s
.
6
0
%
)
p
=
0
.
2
1
-
-
-
-
P
r
o
x
i
m
a
l
c
o
l
o
n
c
a
n
c
e
r
o
n
l
y
[
2
0
]
I
o
n
o
v
e
t
a
l
.
(
2
0
0
0
)
?
5
0
8
-
-
6
7
-
-
3
1
/
3
6
O
S
:
p
=
0
.
5
5
-
1
9
/
3
6
O
S
:
i
n
f
e
r
i
o
r
p
,
0
.
0
1
-
[
2
1
]
W
a
t
a
n
a
b
e
e
t
a
l
.
(
2
0
0
1
)
m
a
n
y
2
9
8
I
I
–
I
I
I
A
d
j
u
v
a
n
t
c
h
e
m
o
-
t
h
e
r
a
p
y
7
3
-
-
4
8
/
7
3
O
S
:
7
4
%
(
v
s
.
4
6
%
)
p
=
0
.
0
4
-
2
2
/
6
0
-
-
M
u
l
t
i
v
a
r
i
a
t
e
m
o
d
e
l
a
s
s
e
s
s
e
d
e
f
f
e
c
t
o
f
M
S
S
v
s
.
M
S
I
-
h
i
g
h
a
n
d
T
G
F
B
R
2
m
u
t
a
t
i
o
n
.
1
8
q
L
O
H
w
a
s
a
l
s
o
a
s
s
e
s
s
e
d
.
[
2
2
]
S
a
m
o
w
i
t
z
e
t
a
l
.
(
2
0
0
2
)
m
a
n
y
1
4
2
7
I
–
I
V
-
1
7
4
-
-
1
3
4
/
1
7
0
O
S
:
7
2
%
(
v
s
.
6
7
%
)
N
S
O
S
:
1
.
0
1
(
0
.
5
4
–
1
.
8
8
)
N
S
6
3
/
1
6
0
O
S
:
6
7
%
(
v
s
.
7
1
%
)
N
S
O
S
:
1
.
3
3
(
0
.
8
0
–
2
.
2
1
)
N
S
C
a
s
e
s
f
r
o
m
8
c
o
u
n
t
y
a
r
e
a
s
[
2
3
]
F
e
r
n
a
´
n
d
e
z
-
P
e
r
a
l
t
a
e
t
a
l
.
(
2
0
0
5
)
1
1
5
5
D
u
k
e
s
’
A
–
D
-
1
6
-
-
1
3
/
1
6
O
S
:
s
u
p
e
r
i
o
r
p
=
0
.
0
4
-
6
/
1
6
O
S
:
s
u
p
e
r
i
o
r
p
,
0
.
0
0
1
-
[
2
4
]
J
u
n
g
e
t
a
l
.
(
2
0
0
6
)
4
1
7
2
I
I
-
4
8
1
1
-
3
5
/
4
5
-
O
S
:
N
S
(
u
n
i
v
a
r
i
a
t
e
H
R
o
n
l
y
)
2
9
/
4
7
-
-
[
2
5
]
K
i
m
e
t
a
l
.
(
2
0
0
7
)
m
a
n
y
5
4
2
D
u
k
e
s
’
B
a
n
d
C
A
d
j
u
v
a
n
t
c
h
e
m
o
-
t
h
e
r
a
p
y
{
9
8
2
6
-
5
4
/
9
8
-
O
S
(
s
t
r
a
t
i
f
i
e
d
b
y
s
t
a
g
e
a
n
d
t
r
e
a
t
m
e
n
t
)
:
1
.
2
6
(
0
.
5
7
–
2
.
8
0
)
N
S
-
-
-
N
a
t
i
o
n
a
l
S
u
r
g
i
c
a
l
A
d
j
u
v
a
n
t
B
r
e
a
s
t
a
n
d
B
o
w
e
l
P
r
o
j
e
c
t
(
N
S
A
B
P
)
S
h
i
m
a
e
t
a
l
.
(
c
u
r
r
e
n
t
s
t
u
d
y
)
m
a
n
y
1
0
7
2
I
–
I
V
-
1
6
2
5
9
2
0
1
1
7
/
1
5
9
C
S
:
8
6
%
(
v
s
.
9
0
%
)
,
p
=
0
.
5
5
O
S
:
6
4
%
(
v
s
.
6
0
%
)
,
p
=
0
.
6
6
C
S
:
1
.
1
8
(
0
.
2
9
–
4
.
8
9
)
,
p
=
0
.
8
2
O
S
:
0
.
6
1
(
0
.
3
2
–
1
.
1
5
)
,
p
=
0
.
1
2
4
8
/
1
5
8
C
S
:
9
2
%
(
v
s
.
8
5
%
)
,
p
=
0
.
2
9
O
S
:
5
6
%
(
v
s
.
6
5
%
)
,
p
=
0
.
3
9
C
S
:
0
.
7
3
(
0
.
2
2
–
2
.
4
1
)
,
p
=
0
.
6
0
O
S
:
1
.
4
6
(
0
.
8
0
–
2
.
6
5
)
,
p
=
0
.
2
2
T
u
m
o
r
m
o
l
e
c
u
l
a
r
c
o
v
a
r
i
a
t
e
s
i
n
c
l
u
d
e
C
I
M
P
,
L
I
N
E
-
1
m
e
t
h
y
l
a
t
i
o
n
,
a
n
d
m
u
t
a
t
i
o
n
s
i
n
K
R
A
S
,
B
R
A
F
a
n
d
P
I
K
3
C
A
.
C
I
,
c
o
n
f
i
d
e
n
c
e
i
n
t
e
r
v
a
l
;
C
I
M
P
,
C
p
G
i
s
l
a
n
d
m
e
t
h
y
l
a
t
o
r
p
h
e
n
o
t
y
p
e
;
C
S
,
c
o
l
o
r
e
c
t
a
l
c
a
n
c
e
r
-
s
p
e
c
i
f
i
c
s
u
r
v
i
v
a
l
;
H
R
,
h
a
z
a
r
d
r
a
t
i
o
;
L
O
H
,
l
o
s
s
o
f
h
e
t
e
r
o
z
y
g
o
s
i
t
y
;
M
S
I
,
m
i
c
r
o
s
a
t
e
l
l
i
t
e
i
n
s
t
a
b
i
l
i
t
y
;
M
S
S
,
m
i
c
r
o
s
a
t
e
l
l
i
t
e
s
t
a
b
l
e
;
N
S
,
n
o
t
s
i
g
n
i
f
i
c
a
n
t
;
O
S
,
o
v
e
r
a
l
l
s
u
r
v
i
v
a
l
;
*
I
n
c
l
u
d
i
n
g
M
S
S
/
M
S
I
-
l
o
w
c
a
s
e
s
.
{
T
h
e
a
u
t
h
o
r
s
(
K
i
m
e
t
a
l
.
[
2
5
]
)
c
o
m
p
a
r
e
d
p
r
e
d
i
c
t
i
v
e
e
f
f
e
c
t
o
f
M
S
I
f
o
r
c
h
e
m
o
t
h
e
r
a
p
y
b
e
t
w
e
e
n
t
h
e
c
a
s
e
s
r
e
g
i
s
t
e
r
e
d
s
u
r
g
e
r
y
a
l
o
n
e
a
n
d
t
h
e
c
a
s
e
s
r
e
g
i
s
t
e
r
e
d
c
h
e
m
o
t
h
e
r
a
p
y
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
2
5
0
6
2
.
t
0
0
1
TGFBR2 and BAX Mutations in Colorectal Cancer
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e25062TGFBR2 or BAX mononucleotide mutation in less than 100 MSI-
high tumors (the number of MSI-high tumors ranging from 16 to
98) [19,20,21,22,23,24,25]. In addition, none of the previous
studies [19,20,21,22,23,24,25] has comprehensively examined
potential confounding effect of key molecular biomarkers in
colorectal cancer, including the CpG island methylator phenotype
(CIMP), and KRAS, BRAF and PIK3CA mutations. Thus, the
prognostic role of TGFBR2 or BAX mononucleotide mutation in
MSI-high tumors still remains uncertain.
We conducted this study to test the hypothesis that TGFBR2 or
BAX mononucleotide mutations in colorectal cancer were
associated with altered tumor behavior (beyond MSI), utilizing a
database of 1072 stage I to IV colorectal cancers in two
prospective cohort studies. Our current study represents the first
study which utilized a database of prospective cohort studies to test
the stated hypothesis. This fact increases generalizability of our
study findings. Moreover, because we concurrently assessed
clinical, pathologic and tumor molecular variables such as the
CpG island methylator phenotype (CIMP), LINE-1 methylation,
KRAS, BRAF and PIK3CA mutations, we could evaluate the effect
of TGFBR2 or BAX mutation independent of these potential
confounders.
Methods
Study group
We utilized the database of two prospective cohort studies, the
Nurses’ Health Study (N=121,701 women followed since 1976)
and the Health Professionals Follow-up Study (N=51,529 men
followed since 1986) [26,27]. Participants have been sent biennial
questionnaires to update information on potential risk factors and
to identify newly diagnosed cancers in themselves and their first
degree relatives. We collected paraffin-embedded tumor tissue
blocks of incident colorectal cancers from hospitals throughout the
U.S. where participants with colorectal cancer underwent tumor
resection [26,27]. Clinical characteristics of the cases are described
in Table 2 (on the left, under the column heading ‘‘All cases’’).
There was no significant difference in demographic features
between cases with tissue available and those without available
tissue among our cohort studies [26]. A majority of cases have
previously been characterized for statuses of TGFBR2, MSI,
CIMP, KRAS, BRAF, PIK3CA and LINE-1 methylation
[28,29,30,31]. However, none of our previous studies have
analyzed the prognostic significance of mononucleotide mutation
of TGFBR2 or BAX. BAX mutation has not been analyzed in any of
our previous studies. Thus, this study represents a new study
utilizing a resource of the existing materials and database,
analogous to novel studies using well-described cell lines (e.g.,
SW480 cell line) or mouse models (e.g., Apc min mouse model).
Hematoxylin and eosin stained tissue sections from all colorectal
cancer cases were reviewed by a pathologist (S.O.) unaware of
other data. Tumor differentiation was categorized as well-
moderate vs. poor (.50% vs. #50% glandular areas). We
excluded cases which were preoperatively treated. Based on the
availability of adequate follow-up and tumor tissue data, 1072
stage I–IV colorectal cancer cases diagnosed up to 2004 were
included in the current study (Figure 1). Patients were observed
until death or June 30 2009, whichever came first. Death of a
participant was confirmed by the National Death Index.
Returning questionnaire indicated informed consent from all
study subjects. Informed consent was obtained from all study
subjects. Tissue collection and analyses were approved by the
Human Subjects Committees at Harvard School of Public Health
and Brigham and Women’s Hospital.
Microsatellite instability (MSI) analysis and detection of
TGFBR2 and BAX mononucleotide tract mutations
DNA was extracted from paraffin embedded tissue. MSI analysis
was performed using 10 microsatellite markers (D2S123, D5S346,
D17S250,BAT25,BAT26,BAT40,D18S55,D18S56,D18S67and
D18S487) [30]. MSI-high was defined as the presence of instability
in $30% of the markers, and MSI-low/microsatellite stable (MSS)
as instability in 0–29% of markers [30]. Mononucleotide tract
mutationsof TGFBR2and BAX were examined inMSI-high tumors.
Primers and PCR conditions for TGFBR2 were previously described
[28]. Primer sequences for BAX were; 59-(FAM) ATCCAGGATC-
GAGCAGGGCG-39 and 59-ACTCGCTCAGCTTCTTGGTG-
39. PCR condition was preheat at 95uC for 5 min, 45 cycles (at 94-
55-72uC for 30-30-30 sec), and extension at 72uCf o r2m i n .P C R
products were electrophoresed and analyzed by ABI 3730 DNA
Analyzer (Applied Biosystems, Foster City, CA).
Pyrosequencing of KRAS, BRAF and PIK3CA
PCR and Pyrosequencing targeted for KRAS (codons 12 and 13)
[32], BRAF (codon 600) [33]and PIK3CA (exons 9 and 20) were
performed as previously described [29].
Methylation analyses for CpG islands and LINE-1
Sodium bisulfite treatment and subsequent real-time PCR
(MethyLight [34]) were previously validated [35], and performed
to quantify promoter methylation in eight CpG islands (CACNA1G,
CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1)
[36,37,38]. CIMP-high was defined as the presence of $6/8
methylated markers, CIMP-low as the presence of 1/8 to 5/8
methylated markers, and CIMP-0 as the absence (0/8) of
methylated markers [37,39]. LINE-1 methylation levels were
quantified by PCR-Pyrosequencing [40,41].
Statistical analysis
We used SAS program (Version 9.1, SAS Institute, Cary, NC)
for all statistical analyses. All p values were two-sided. When we
perform multiple hypothesis testing (i.e., analyses of molecular
correlates and interactions), a p value for statistical significance
was adjusted to p=0.0038 (=0.05/13) by Bonferroni correction.
The chi-square test (or Fisher’s exact test) was performed for
categorical variables. The t test assuming unequal variances was
done to compare mean age and mean LINE-1 methylation level.
For survival analysis, the Kaplan-Meier method and log-rank test
were used. For analyses of colorectal cancer-specific mortality,
deaths as a result of causes other than colorectal cancer were
censored. To control for confounding, we used multivariate stage-
matched (stratified) Cox proportional hazards model to compute
hazard ratio (HR) of death. To avoid residual confounding and
overfitting, disease stage (I, II, III, IV, unknown) was used as a
stratifying variable, utilizing the ‘‘strata’’ option in the SAS ‘‘proc
phreg’’ command. The multivariate model initially included age at
diagnosis (continuous), sex, year of diagnosis (continuous), body
mass index (BMI; ,30 vs. $30 kg/m
2), family history of
colorectal cancer in any first degree relative (present vs. absent),
tumor location (proximal vs. distal), tumor differentiation (well-
moderate vs. poor), CIMP (high vs. low/CIMP-0), LINE-1
methylation (continuous), KRAS, BRAF and PIK3CA. A backward
elimination method with a threshold of p=0.20 was used to limit
the number of variables in the final model and avoid overfitting.
For cases with missing information in any of the categorical
variables [BMI (0.1%), tumor location (1.0%), tumor grade (0.6%),
CIMP (2.5%), KRAS (0.5%), BRAF (0.7%) and PIK3CA (8.8%)], we
included those cases in a majority category of a given covariate to
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e25062Table 2. MSI status and TGFBR2 or BAX mononucleotide tract mutation in colorectal cancer.
Clinical, pathologic
or molecular feature Total N
MSS/MSI-
low MSI-high
TGFBR2 mononucleotide
mutation in MSI-high tumors
BAX mononucleotide
mutation in MSI-high tumors
(2)( +) P value (2)( +) P value
All cases 1072 910 162 42 117 110 48
Sex 0.45 0.51
Female (NHS) 603 (56%) 495 (54%) 108 (67%) 26 (62%) 80 (68%) 72 (65%) 34 (71%)
Male (HPFS) 469 (44%) 415 (46%) 54 (33%) 16 (38%) 37 (32%) 38 (35%) 14 (29%)
Mean age 6 SD 67.568.5 67.268.6 69.567.3 68.367.6 69.767.0 0.26 68.767.4 70.666.4 0.13
Body mass index 0.34 0.62
,30 kg/m
2 871 (81%) 740 (81%) 131 (81%) 32 (76%) 97 (83%) 88 (80%) 40 (83%)
$30 kg/m
2 200 (19%) 169 (19%) 31 (19%) 10 (24%) 20 (17%) 22 (20%) 8 (17%)
Family history of
colorectal cancer
0.68 0.56
Absent 866 (81%) 743 (82%) 123 (76%) 31 (74%) 90 (77%) 85 (77%) 35 (73%)
Present 206 (19%) 167 (18%) 39 (24%) 11 (26%) 27 (23%) 25 (23%) 13 (27%)
Year of diagnosis 0.28 0.68
Prior to 1995 390 (36%) 347 (38%) 43 (26%) 14 (33%) 29 (25%) 31 (28%) 12 (25%)
1995 to 2004 682 (64%) 563 (62%) 119 (73%) 28 (67%) 88 (75%) 79 (72%) 36 (75%)
Tumor location 0.12 0.51
Proximal colon
(cecum to transverse)
492 (47%) 351 (39%) 141 (87%) 35 (83%) 105 (90%) 95 (86%) 44 (92%)
Distal colon 337 (32%) 321 (36%) 16 (9.9%) 4 (10%) 11 (9.4%) 11 (10%) 4 (8.3%)
Rectum 228 (22%) 223 (25%) 5 (3.1%) 3 (7.1%) 1 (0.9%) 4 (3.6%) 0
Disease stage 0.045 0.014
I 256 (24%) 224 (25%) 32 (20%) 15 (36%) 17 (15%) 26 (24%) 6 (13%)
II 308 (29%) 221 (24%) 87 (54%) 18 (43%) 66 (56%) 48 (44%) 35 (73%)
III 282(26%) 256 (28%) 26 (16%) 4 (9.5%) 22 (19%) 21 (19%) 5 (10%)
IV 146 (14%) 136 (15%) 10 (6.2%) 3 (7.1%) 7 (6.0%) 8 (7.3%) 2 (4.2%)
unknown 80 (7.5%) 73 (8.0%) 7 (4.3%) 2 (4.8%) 5 (4.3%) 7 (6.4%) 0
Tumor grade 0.86 0.19
Low 962 (90%) 851 (94%) 111 (69%) 29 (69%) 79 (68%) 78 (71%) 29 (60%)
High 104 (10%) 53 (5.9%) 51 (31%) 13 (31%) 38 (32%) 32 (29%) 19 (40%)
CIMP status 0.0010 0.52
CIMP-0 462 (44%) 450 (51%) 12 (7.5%) 3 (7.3%) 9 (7.8%) 9 (8.3%) 3 (6.3%)
CIMP-low 411 (39%) 382 (43%) 29 (18%) 15 (37%) 12 (10%) 21 (19%) 6 (13%)
CIMP-high 172 (16%) 53 (6.0%) 119 (74%) 23 (56%) 95 (82%) 78 (72%) 39 (81%)
KRAS mutation 0.016 0.81
(2) 684 (64%) 546 (60%) 138 (86%) 31 (76%) 105 (91%) 93 (86%) 42 (88%)
(+) 383 (36%) 361 (40%) 22 (14%) 10 (24%) 11 (9.5%) 15 (14%) 6 (13%)
BRAF mutation 0.0049 0.59
(2) 915 (86%) 835 (92%) 80 (50%) 28 (68%) 50 (43%) 55 (50%) 22 (46%)
(+) 150 (14%) 69 (7.6%) 81 (50%) 13 (32%) 67 (57%) 54 (49%) 26 (54%)
PIK3CA mutation 0.53 0.079
(2) 789 (81%) 679 (82%) 110 (76%) 26 (72%) 82 (77%) 71 (72%) 37 (86%)
(+) 189 (19%) 154 (18%) 35 (24%) 10 (28%) 24 (23%) 27 (28%) 6 (14%)
Mean LINE-1 methylation
(%) 6 SD
62.069.4 61.269.3 66.168.5 66.269.8 65.968.0 0.83 66.068.6 66.068.4 0.96
(%) indicates the proportion of cases with a specific clinical, pathologic or molecular feature among all cases, MSS/MSI-Low, TGFBR2 mutated or BAX mutated cases.
CIMP, CpG island methylator phenotype; HPFS, Health Professionals Follow-up Study; MSI, microsatellite instability; MSS, microsatellite stable, NHS, Nurses’ Health
Study; SD, standard deviation.
doi:10.1371/journal.pone.0025062.t002
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information in any of the covariates did not substantially alter
results (data not shown).
A multivariate logistic regression analysis was performed to
examine an independent relationship of each covariate with TGFBR2
mutation (as an outcome variable). The multivariate model initially
included a similar, but not the same set of the covariates as the initial
Cox model, considering possible cause-effect relationship with
TGFBR2 mutation. Specifically, disease stage and tumor differentia-
tion were likely consequences (rather than causes) of TGFBR2
mutation. Thus, those variables were not included in the logistic
regression model. A backward elimination with a threshold of p=0.10
was used to select variables in the final model and avoid overfitting.
Results
Mononucleotide mutations of TGFBR2 and BAX in MSI-
high colorectal cancers
Among 1072 colorectal cancers in the two prospective cohort
studies, MSI-high was observed in 162 (15%) tumors. TGFBR2
and BAX mononucleotide tract mutations were detected in 117 (of
159, 74%) and 48 (of 158, 30%) MSI-high tumors, respectively.
Among MSI-high tumors, TGFBR2 mutation was significantly
associated with CIMP-high (p=0.0010) (Table 2).
Multivariate analysis to assess independent relations with
TGFBR2 mutation
We performed multivariate logistic regression analysis to
examine whether TGFBR2 mutation was independently associated
with any clinical, pathologic and other molecular variables. In
MSI-high tumors, TGFBR2 mutation was independently associat-
ed with CIMP-high [multivariate odds ratio (OR), 3.57; 95%
confidence interval (CI), 1.66–7.66; p=0.0011].
Mononucleotide mutations of TGFBR2 and BAX and
colorectal cancer prognosis
During adequate follow-up (11.6 years of median follow-up of
censored cases), there were 505 deaths including 302 colorectal
cancer-specific deaths. Among all cases, MSI-high was significantly
associated with longer colorectal cancer-specific survival compared
to MSS/MSI-low cancers by log-rank test (p,0.0001), univariate
and multivariate Cox regression analysis (adjusted HR, 0.34; 95%
CI, 0.20–0.57; p,0.0001) (Table 3). When we separately
examined TGFBR2-mutated MSI-high cases and TGFBR2-wildtype
MSI-high cases, both groups showed significantly longer colorectal
cancer-specific survival compared to MSS/MSI-low cases
(Figure 2, Table 3). When we separately examined BAX-mutated
MSI-high cases and BAX-wildtype MSI-high cases, both groups
Figure 1. Flow diagram of the current study. Based on the
availability of adequate follow-up and tumor molecular data among
incident colorectal cancers identified in the Nurses’ Health Study (NHS;
N=121,701) and the Health Professionals Follow-up Study (HPFS;
N=51,529), a total of 1072 stage I–IV colorectal cancer cases diagnosed
up to 2004 were included. MSI, microsatellite instability; MSS,
microsatellite stable.
doi:10.1371/journal.pone.0025062.g001
Table 3. MSI status, TGFBR2 and BAX mononucleotide tract mutation and survival of colorectal cancer patients.
Colorectal cancer-specific mortality Overall mortality
Total N
Deaths/
person-years
Univariate
HR (95% CI)
Multivariate
stage-matched
HR (95% CI)
Deaths/
person-years
Univariate
HR (95% CI)
Multivariate
stage-matched
HR (95% CI)
MSS/MSI-low tumors 910 282/8015 1 (referent) 1 (referent) 445/8015 1 (referent) 1 (referent)
MSI-high tumors 162 20/1468 0.37 (0.24–0.58) 0.34 (0.20–0.57) 60/1468 0.72 (0.55–0.94) 0.64 (0.47–0.89)
MSI-high tumors
TGFBR2 mutation (2) 42 4/390 0.30 (0.11–0.79) 0.29 (0.10–0.83) 17/390 0.79 (0.48–1.28) 0.79 (0.47–1.34)
TGFBR2 mutation (+) 117 16/1060 0.41 (0.25–0.67) 0.35 (0.20–0.62) 42/1060 0.69 (0.50–0.95) 0.59 (0.41–0.86)
BAX mutation (2) 110 16/999 0.44 (0.27–0.73) 0.36 (0.20–0.62) 38/999 0.67 (0.48–0.93) 0.57 (0.39–0.84)
BAX mutation (+) 48 4/443 0.25 (0.09–0.66) 0.30 (0.11–0.83) 21/443 0.84 (0.54–1.30) 0.82 (0.50–1.32)
The multivariate, stage-matched (stratified) Cox regression model initially included the TGFBR2 mutation or BAX mutation variable, sex, age at diagnosis, year of
diagnosis, tumor location, body mass index, family history of colorectal cancer, tumor grade, CIMP, KRAS, BRAF, PIK3CA and LINE-1 methylation. A backward elimination
with a threshold of p=0.20 was used to select variables in the final models. Stage adjustment (I, II, III, IV, unknown) was done using the ‘‘strata’’ option in the SAS ‘‘proc
phreg’’ command.
CI, confidence interval; HR, hazard ratio; MSI, microsatellite instability; MSS, microsatellite stable.
doi:10.1371/journal.pone.0025062.t003
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compared to MSS/MSI-low cases (Figure 2, Table 3). In overall
mortality analyses, although somewhat attenuated, results showed
similar trends (Table 3). Among MSI-high cases, patient survival
did not significantly differ by TGFBR2 or BAX mutation status.
We compared colorectal cancer specific and overall survival
between TGFBR2-mutated MSI-high cases and TGFBR2-wildtype
MSI-high cases (or between BAX-mutated MSI-high cases and
BAX-wild type MSI-high cases). There was no significant
difference between the two groups (Table 1).
Figure 2. Kaplan-Meier curves according to MSI status and TGFBR2 or BAX mononucleotide mutation in colorectal cancer. Kaplan-
Meier curves for colorectal cancer-specific survival (A) and overall survival (B), according to TGFBR2 mononucleotide mutation status. Regardless of
TGFBR2 status, MSI-high cases were associated with longer survival. Kaplan-Meier curves for colorectal cancer-specific survival (C) and overall survival
(D), according to BAX mononucleotide mutation status. Regardless of BAX status, MSI-high cases were associated with longer survival. MSI,
microsatellite instability; MSS, microsatellite stable.
doi:10.1371/journal.pone.0025062.g002
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We conducted this study to examine the prognostic significance
of mononucleotide tract mutations in the coding regions of
TGFBR2 or BAX in MSI-high colorectal cancers. We utilized two
prospective cohort studies with a large number of clinically and
molecularly well-annotated colorectal cancer cases with adequate
follow-up. Our result showed that MSI-high tumors were
associated with indolent tumor behavior regardless of TGFBR2
or BAX mononucleotide mutation status, independent of CIMP
and other key tumor molecular biomarkers. Nonetheless, it may be
of interest to examine interactions between these molecular
alterations and dietary and lifestyle factors if there is a hypothesis
in evolving science of molecular pathological epidemiology
[42,43].
It should be noted that small studies are more prone to
‘‘publication bias’’ than large studies [44]. This phenomenon of
publication bias occurs because studies with null findings have a
higher likelihood of being unwritten and unpublished compared to
those with significant results. Compared to small studies (e.g.,
studies with a sample size of ,200 cancers) with null data, large
studies with null data are more likely published. As a result, large
studies are less prone to publication bias than small studies.
Furthermore, academic pressures might force investigators to
design small studies which are easy to complete and get data for
haste publications, which might contribute to bias [45,46,47].
Therefore, we should weigh more on large-scale studies when we
evaluate the published literature on prognostic significance of any
biomarker such as TGFBR2 or BAX mononucleotide mutation.
Publishing null data in well-powered studies [44,48,49,50,51,52]
are important because publishing significant results in small
underpowered studies leads to publication bias.
Our data are generally consistent with some of previous studies
[19,22,24,25] (Table 1). Watanabe et al. [21] used stage II and III
cases that underwent adjuvant chemotherapy, and reported that,
TGFBR2 mutation was associated with improved 5-year overall
survival among 73 MSI-high tumors. In another study [20],
among 67 MSI-high tumors, BAX mutation was associated with
poor prognosis. In an underpowered study by Ferna ´ndez-Peralta
et al. [23], among 16 MSI-high tumors, both TGFBR2 mutation
and BAX mutation were associated with better prognosis. The
largest study (total N=1427; 170 MSI-high cancers) by Samowitz
et al. [22] showed no prognostic role of TGFBR2 or BAX
mutations among MSI-high colorectal cancer cases, in agreement
with our current study - the second largest study to date and the
only study which examined other key tumor molecular biomarkers
such as CIMP, LINE-1 methylation and KRAS, BRAF and PIK3CA
mutations.
Studying somatic molecular changes and molecular correlates is
important in cancer research towards personalized medicine
[53,54,55,56]. The CpG island methylator phenotype (CIMP)
has been established as an epigenomic molecular classifier of
colorectal cancer [57,58,59,60,61,62,63,64,65,66,67,68,69,70,71].
In the past, Iacopetta et al. [20] showed no significant association
between KRAS mutation and TGFBR2 mutation. We assessed the
association between tumor molecular variables (CIMP, LINE-1,
KRAS, BRAF and PIK3CA) and TGFBR2 mutation and did not find
significant relation between TGFBR2 mutation and KRAS or BRAF
mutation. Interestingly, we have found that, among MSI-high
tumors, TGFBR2 mutation was associated with CIMP-high,
independent of clinical and other molecular features. A recent
study [72] has reported that genetic variants in the TGFB1
pathway related genes (MAPK1, RUNX1 and RUNX2) are
associated with CIMP-high colon cancer. Further studies are
needed to elucidate the exact mechanism of the relationship
between CIMP and the TGFB1 pathway.
There are limitations in this study. For example, data on cancer
treatment were limited. Nonetheless, it is unlikely that chemo-
therapy use substantially differed according to TGFBR2 or BAX
mutation status in tumor, since such data were typically
unavailable for treatment decision making. As another limitation,
beyond cause of mortality, data on cancer recurrences were
unavailable in these cohort studies. Nonetheless, given median
follow-up of over 11 years for censored cases, colorectal cancer-
specific survival might be a reasonable surrogate of colorectal
cancer-specific outcome.
There are advantages in utilizing the database of the two
prospective cohort studies, the Nurses’ Health Study and the
Health Professionals Follow-up Study, to examine prognostic
significance of tumor biomarkers. Anthropometric measurements,
family history, cancer staging, and other clinical, pathologic, and
tumor molecular data were prospectively collected, blinded to
patient outcome [26]. Cohort participants who developed cancer
were treated at hospitals throughout the U.S., and thus more
representative colorectal cancers in the U.S. population than
patients in one to a few academic hospitals. There were no
demographic difference between cases with tumor tissue analyzed
and those without tumor tissue analyzed [26]. Finally, our rich
tumor database enabled us to simultaneously assess pathologic and
tumor molecular correlates and control for potential confounding
by the tumor molecular features.
In conclusion, our large tumor database has shown that,
compared to MSS/MSI-low cases, MSI-high colorectal cancer is
associated with longer cancer-specific survival, regardless of
TGFBR2 or BAX mononucleotide tract mutation status. The
importance of large-scale studies cannot be overemphasized
because, compared to large studies, small studies are much more
prone to publication bias, which can mislead clinical practice.
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